Gene therapies have evolved significantly over the past several years, largely thanks to viral vectors.
Adeno-associated virus (AAV) and lentivirus (LV) vectors are increasingly prominent in the gene transfer space. The vectors account for half of the current vector-related clinical trials worldwide, according to research published in Signal Transduction and Targeted Therapy. The other half? Adenoviruses, a research mainstay with concerns about immunogenicity.
AAV and LV vectors can be appealing alternatives to adenoviruses for researchers engaged in viral vector work. For one, they can each infect dividing and nondividing cells. There's also less risk of a significant immune response from the host.
But despite their similarities, their differences affect applications and workflows, especially regarding purity and viability.